Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is a leading radiopharmaceutical company with a strong pipeline and a proven track record of success in developing and commercializing radiopharmaceutical treatments for cancer. With FDA alignment on the design of its Phase 3 ProstACT Global study and encouraging data from its Phase 1 trial, Telix is poised for continued growth and potential to become the standard of care for prostate cancer. With its differentiated biodistribution, favorable dosimetry profile, and convenient dosing regimen, Telix's leading candidate TLX591 has the potential to replace Pluvicto as the standard treatment for prostate cancer, making it a promising investment opportunity.

Bears say

Telix Pharmaceuticals is currently experiencing a low customer demand for its lead product Illuccix, and it faces potential delays in regulatory approvals and clinical trials for its pipeline products TLX591/592, TLX250, TLX101, and TLX66 which make up a significant portion of its revenue forecast. These risks, coupled with the company's high valuation of 8x multiple to 2031-2032 estimated sales and 5x multiple to 2025 estimated sales, make it a risky investment with limited potential for growth in the near future.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.